Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Thursday

Akero Therapeutics (NASDAQ:AKRO) will likely be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Akero Therapeutics to post earnings of ($0.98) per share for the quarter.

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $47.67 on Thursday. The firm has a market capitalization of $3.33 billion, a P/E ratio of -12.71 and a beta of -0.11. Akero Therapeutics has a one year low of $17.86 and a one year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The business has a fifty day moving average price of $38.14 and a 200-day moving average price of $32.23.

Insider Transactions at Akero Therapeutics

In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the completion of the sale, the chief executive officer now owns 686,062 shares of the company’s stock, valued at $36,176,049.26. The trade was a 4.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jonathan Young sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $32.13, for a total value of $321,300.00. Following the transaction, the chief operating officer now owns 206,286 shares in the company, valued at $6,627,969.18. This trade represents a 4.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 208,992 shares of company stock valued at $9,633,413 in the last quarter. Insiders own 7.94% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on AKRO shares. Citigroup raised their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. UBS Group raised their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Canaccord Genuity Group upped their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Morgan Stanley raised their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Finally, HC Wainwright upped their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.